c-RET
Read More about this categoryShow Less
The c-RET proto-oncogene, which was originally identified as a transforming gene by transfection of T-cell lymphoma DNA into NIH3T3 cells, is a member of the receptor tyrosine kinase (RTK) gene superfamily that encodes a receptor tyrosine kinase involved in the regulation of glial cell line-derived neurotrophic factor (GDNF) signaling. Signaling proteins, such as Grb7/Grb10, PLCγ, Shc/Enigma and Grb2, are recruited by activated c-RET protein through binding to the phosphorylated tyrosine residues in c-RET protein’s COOH-terminal sequence, Y905, Y1015, Y1062 and Y1096 respectively. Moreover, results of in vivo studies suggest mutations of c-RET have been implicated in tumorigenesis, in which c-RET mRNA and/or protein have been found in tumors of neuroectodermal origin as well as in human neuroblastoma cell lines.
Products Related to c-RET(8)
- GC16362AD57 (hydrochloride)CAS: 2320261-72-9Purity: >98%
polypharmacological cancer therapeutic that inhibits RET.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC10035 | TG101209 | 936091-14-4 | >99.50% | |
An inhibitor of JAK2, FLT3, RET, and JAK3 | ||||
| GC13194 | RPI-1 | 269730-03-2 | >98.50% | |
ATP-dependent RET kinase inhibitor | ||||
| GC14534 | Regorafenib monohydrate | 1019206-88-2 | >99.50% | |
A multi-kinase inhibitor | ||||
| GC14606 | Regorafenib hydrochloride | 835621-07-3 | >99.50% | |
A multi-kinase inhibitor | ||||
| GC15217 | Danusertib (PHA-739358) | 827318-97-8 | >98.50% | |
A pan-Aurora kinase and Abl inhibitor | ||||
| GC15307 | SU5416 | 204005-46-9 | >98.00% | |
SU5416 is a small-molecule Flk-1/KDR inhibitor that inhibits autophosphorylation of the Flk-1 receptor, with an IC 50 value of 1.23μM. | ||||
| GC16362 | AD57 (hydrochloride) | 2320261-72-9 | >98% | |
polypharmacological cancer therapeutic that inhibits RET. | ||||
| GC16391 | Amuvatinib (MP-470, HPK 56) | 850879-09-3 | >98.00% | |
A multi-targeted RTK inhibitor | ||||
